Table 1.
Baseline Characteristics of Subjects by Study Group
| Median (interquartile range) or no. (%) | All Subjects N = 135 |
Statin Group N = 67 |
Placebo Group N = 68 |
|---|---|---|---|
| Age (years) | 47 (39, 53) | 47 (41, 52) | 47 (37, 53) |
| Male sex | 109 (81%) | 55 (82%) | 54 (79%) |
| African American race | 91 (67%) | 46 (69%) | 45 (66%) |
| BMI (kg/m2) | 26.7 (23.3, 30.2) | 26.6 (23.3, 30.7) | 27.0 (23.2, 30.2) |
| Systolic BP (mmHg) | 121 (112, 132) | 121 (111, 132) | 121 (112, 132) |
| Diastolic BP (mmHg) | 80 (72, 84) | 79 (72, 84) | 80 (72, 84) |
| LDL cholesterol (mg/dL) | 96 (77, 113) | 95 (75, 107) | 97 (78, 121) |
| HDL cholesterol (mg/dL) | 45 (37, 57) | 45 (37, 58) | 46 (37, 57) |
| Triglycerides (mg/dL) | 115 (84, 189) | 103 (77, 199) | 122 (87, 187) |
| HOMA-IR | 1.8 (1.1, 3.3) | 1.7 (1.0, 2.8) | 1.9 (1.2, 4.8) |
| Current smoking | 90 (67%) | 40 (60%) | 50 (74%) |
| HIV duration (months) | 136 (70, 213) | 129 (70, 196) | 142 (72, 233) |
| HIV-1 RNA ≤50 copies/mL | 109 (81%) | 54 (81%) | 55 (81%) |
| HIV-1 RNA if >50 copies/mL | 99 (75, 175) | 82 (71, 123) | 131 (81, 178) |
| Current CD4 count (cells/μL) | 578 (432, 836) | 605 (435, 850) | 569 (422, 828) |
| Nadir CD4 count (cells/μL) | 177 (89, 293) | 170 (86, 312) | 190 (90, 279) |
| Cumulative NRTI duration (months) | 62 (38, 115) | 59 (30, 115) | 62 (41, 112) |
| Cumulative PI duration (months) | 39 (7, 89) | 39 (13, 106) | 39 (2, 80) |
| Cumulative NNRTI duration (months) | 24 (6, 54) | 19 (2, 56) | 30 (10, 54) |
| Kallistatin (μg/mL) | 28.4 (19.2, 40.0) | 30.5 (18.4, 39.5) | 26.5 (20.0, 41.1) |
| CD8+CD38+HLA-DR+ (%)* | 12.3 (8.8, 17.4) | 13.4 (9.0, 19.5) | 11.5 (8.5, 16.4) |
| hsCRP (μg/mL) | 1.71 (0.77, 5.02) | 1.66 (0.77, 4.91) | 2.01 (0.72, 5.12) |
| IL-6 (pg/mL) | 2.79 (1.96, 4.74) | 2.89 (1.89, 4.63) | 2.65 (1.97, 5.32) |
| sTNFR-I (pg/mL) | 1610 (1278, 2396) | 1623 (1341, 2200) | 1594 (1236, 2467) |
| sTNFR-II (pg/mL) | 2332 (1625, 2883) | 2474 (1718, 3054) | 2158 (1605, 2629) |
| sVCAM-1 (ng/mL) | 670 (563, 819) | 694 (574, 825) | 643 (544, 750) |
| sICAM-1 (ng/mL) | 237 (185, 308) | 225 (185, 317) | 257 (180, 305) |
| D-dimer (μg/mL) | 0.19 (0.11, 0.32) | 0.20 (0.13, 0.34) | 0.16 (0.09, 0.29) |
| Fibrinogen (mg/dL) | 385 (335, 503) | 388 (339, 513) | 383 (331, 470) |
| CCA IMT (mm) | 0.66 (0.62, 0.76) | 0.66 (0.62, 0.78) | 0.67 (0.60, 0.75) |
| FMD % | 3.9 (2.0, 6.0) | 4.0 (2.0, 6.3) | 3.7 (1.7, 5.3) |
| CAC score >0 | 51 (38%) | 23 (34%) | 28 (41%) |
N.B. There were no significant differences between the statin and placebo groups for any of the variables listed in this table.
% of CD8+ cells expressing CD38 and HLA-DR antigens
BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; NRTI, nucleoside/nucleotide analogue reverse transcriptase inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside/nucleotide analogue reverse transcriptase inhibitor; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; sTNFR-I, soluble tumor necrosis factor receptor-I; sTNFR-II, soluble tumor necrosis factor receptor-II; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble intracellular adhesion molecule-1; CCA IMT, common carotid artery intima-media thickness; FMD, flow-mediated vasodilation; CAC, coronary artery calcium